Gold, Mitchell
About Gold, Mitchell
Mitchell Gold is the Co-founder, Executive Chairman, and CEO of Alpine Immune Sciences, where he has worked since 2015. He holds a Doctor of Medicine degree from Rush Medical College and has extensive experience in the medical field, including a previous role as President and CEO of Dendreon.
Work at Alpine Immune Sciences
Mitchell Gold serves as the Co-founder, Executive Chairman, and CEO of Alpine Immune Sciences. He has held this position since 2015, contributing to the company's mission in the biotechnology sector. Under his leadership, Alpine Immune Sciences focuses on developing innovative therapies that harness the immune system to treat various diseases. His role involves strategic decision-making and overseeing the company's operations in Seattle.
Education and Expertise
Mitchell Gold has a strong educational background in the medical field. He earned a Bachelor of Science degree from the University of Wisconsin-Madison, where he studied Biology from 1985 to 1989. He then attended Rush Medical College of Rush University Medical Center, obtaining his Doctor of Medicine (MD) degree from 1989 to 1993. Following this, he pursued further specialization in Urology at the University of Washington - School of Medicine from 1993 to 1998.
Background
Mitchell Gold has extensive experience in the biotechnology and medical sectors. Before co-founding Alpine Immune Sciences, he served as President and CEO of Dendreon from 2001 to 2012. His tenure at Dendreon was marked by significant advancements in cancer treatment, particularly in the development of immunotherapy. His background in medicine and leadership positions has equipped him with the skills necessary to navigate complex healthcare challenges.
Achievements
Throughout his career, Mitchell Gold has been involved in key leadership roles that have influenced the biotechnology landscape. His work at Dendreon contributed to the advancement of cancer immunotherapy, while his current role at Alpine Immune Sciences focuses on developing innovative immune-based therapies. His educational credentials and professional experiences reflect a commitment to improving patient outcomes through scientific innovation.